Looking for a small stock with big return potential? Jim Cramer thinks you should consider this.» Read More
April 26- BioMarin Pharmaceutical Inc:. *Jefferies raises target price to $72 from $70; rating buy. Reuters Station users, click. 1568.
April 25- BioMarin Pharmaceutical Inc:. *RBC raises target price to $66 from $64; rating outperform. Reuters Station users, click. 1568.
Looking for a small stock with big return potential? Jim Cramer thinks you should consider this.
Had you picked stocks thoughtfully and carefully since Mad Money began, you would have beaten the S&P by 3000%!
The "Mad Money" host comments on viewers' favorite stocks!
These four biotech stocks could take a big hit when investors start to focus on lower-valued stocks in other industries. TheStreet.com reports.
The big U.S. and European drug companies are dealing with their own 'cliff' as blockbuster drugs lose their patent protection. But they are turning back to research and development to fill the gap.
Jim Cramer’s researcher Nicole Urken reviews the potential biotech pipeline winners there were highlighted this week on Mad Money.
SAN FRANCISCO Jan 8- BioMarin Pharmaceutical Inc, which makes high-priced drugs used to treat rare diseases, would not consider a buy-out offer for even a 25-30 percent premium, according to the company's chief executive officer.
The iShare Biotech ETF is up 32 percent over the past year. Jean-Jacques Bienaime, BioMarin Pharmaceutical CEO, discusses the reason behind his company behind up 24.9 percent in the last 3 months.
SAN FRANCISCO Jan 8- BioMarin Pharmaceutical Inc, which makes high-priced drugs used to treat rare diseases, has been approached by potential acquirers but would not sell itself for even a 25-30 percent premium, according to the company's chief executive officer.
Strong fundamentals and dominant market positions make three biotech/pharma names stand out, Barbara Ryan says.
Jan 3- Rare diseases are a growing focus for drug companies, with prices for some treatments for ultra-rare conditions running into hundreds of thousands of dollars a year. Forecast 2012 sales: $1.1 billion. Forecast 2012 sales: $830 million.
*$50 bln rare diseases sector out-growing rest of market. LONDON, Jan 3- The Western world's first drug to fix faulty genes promises to transform the lives of patients with an ultra-rare disease that clogs their blood with fat.
TheStreet.com offers up 13 biotech predictions for 2013.